IMVT - Immunovant, Inc.

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
+0.06 (+0.29%)
收市:04:00PM EDT
20.77 -0.27 (-1.28%)
收市後: 07:14PM EDT
買盤0.00 x 900
賣出價0.00 x 900
今日波幅20.77 - 21.35
52 週波幅3.14 - 24.18
Beta 值 (5 年,每月)1.02
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-1.68
業績公佈日2023年8月03日 - 2023年8月07日
遠期股息及收益率無 (無)
1 年預測目標價26.50
  • InvestorPlace

    The Quant Trading System Picking Stocks That Soar 300%

    Editor’s note: “The Quant Trading System Picking Stocks That Soar 300%” was previously published in January 2023. It has since been updated to include the most relevant information available. The stock market got crushed in 2022. It was a nasty year for most investors. But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly picking stocks that were soaring 100%, 200%, and even 300%-plus in a matter of months? InvestorPlace - St

  • Benzinga

    Immunovant Could Potentially Be An M&A Target, Writes Analyst

    Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30. The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, fully human, monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn). Batoclimab has demonstrated its potential to reduce immunoglobulin G (IgG) antibodies that cause inflammation, while IMVT-1402 has also demonstrated profound IgG antibody reduction in animal studies. Related:

  • Insider Monkey

    12 Best Small-Cap Healthcare Stocks To Buy Now

    In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. […]

  • Benzinga

    Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

    On Wednesday, Immunovant Inc (NASDAQ: IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody that matches batoclimab's IgG lowering without affecting albumin and LDL. HC Wainwright says the addition of IMVT-1402 broadens the anti-FcRn franchise. The analyst maintains a Buy rating with a price target of $16. Roivant is leveraging data and learnings from batoclimab studies to accelerate IMVT-1402's develop

  • Insider Monkey

    These 10 Stocks are Getting Crushed on Monday

    In this article, we will take a look at the 10 stocks getting crushed on Monday. If you want to see some more companies on the list, go directly to These 5 Stocks are Getting Crushed on Monday. U.S. stocks inched up before the opening bell today. However, the gains couldn’t continue for long. All […]

  • Benzinga

    Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year

    View more earnings on IMVTSee more from BenzingaModerna's Updated COVID-19 Shot Boosts Omicron ProtectionThe Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial DataDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga does not provide investment advice. All rights reserved.